GBA1 and Parkinson disease: Evidence of cholinergic changes in GBA1 mutation carriers is restricted to one cholinergic PET study, reporting more widespread cortical cholinergic deficits in PD-GBA1 compared to idiopathic PD when both groups are compared to healthy controls22.